Curevac AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Curevac AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0469
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Curevac AG (Curevac), formerly CureVac GmbH is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA technology platforms include RNArt, RNActive, RNAntibody, and RNAdjuvant. Curevac’s RNActive technology is used to develop treatments against cancer and prophylactic vaccines for infectious diseases. The company’s RNAdjuvant technology is used to enhance the immune response of other vaccines. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. It operates through pharmaceutical companies and research institutes. CureVac is headquartered in Tubingen, Germany.

Curevac AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Curevac AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Partnerships 12
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12
Eli Lilly and CureVac Enter into Partnership 13
International AIDS Vaccine Partners with CureVac 14
CureVac to Enter into Development Agreement with Bill & Melinda Gates 15
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16
Licensing Agreements 17
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
Equity Offering 21
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG – Key Competitors 23
Curevac AG – Key Employees 24
Curevac AG – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Strategy And Business Planning 26
Jan 10, 2018: CureVac Highlights Key 2018 Corporate Milestones and Outlook 26
Oct 30, 2017: CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics 27
Corporate Communications 28
May 08, 2018: CureVac Announces New Management Structure 28
Government and Public Interest 29
Feb 13, 2018: CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria 29
Product News 30
Oct 23, 2017: Publication in npj Vaccines Demonstrates CureVac’s RNActive Vaccine is Superior to Licensed Vaccines 30
Clinical Trials 31
Oct 27, 2017: CureVac Initiates Phase I Clinical Trial of RNAdjuvant Candidate as Intratumoral Therapy for Solid Tumors 31
Other Significant Developments 32
Jun 26, 2017: CureVac Expands GMP Production Capacities for RNA Products 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Curevac AG, Pharmaceuticals & Healthcare, Key Facts 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curevac AG, Deals By Therapy Area, 2012 to YTD 2018 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Curevac and Arcturus Therapeutics Enter into Co-Development Agreement 12
Eli Lilly and CureVac Enter into Partnership 13
International AIDS Vaccine Partners with CureVac 14
CureVac to Enter into Development Agreement with Bill & Melinda Gates 15
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 16
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG, Key Competitors 23
Curevac AG, Key Employees 24
Curevac AG, Other Locations 25
Curevac AG, Subsidiaries 25

List of Figures
Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curevac AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Curevac AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Polimex-Mostostal SA (PXM):企業の財務・戦略的SWOT分析
    Polimex-Mostostal SA (PXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Genesis Energy Ltd:発電所・企業SWOT分析
    Genesis Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Avitide Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avitide Inc (Avitide) strives to discover, manufacture and commercialize molecule-specific affinity purification solutions for biopharmaceutical industry. It offers affinity purification resins for developing bio-molecules including enzymes, non-antibody therapeutics, bispecific antibodies, …
  • CIMIC Group Ltd (CIM):企業の財務・戦略的SWOT分析
    CIMIC Group Ltd (CIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報
    Summary Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG …
  • Orascom Development Egypt Sae:企業の戦略・SWOT・財務分析
    Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report Summary Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • NextEra Energy Inc (NEE)-エネルギー分野:企業M&A・提携分析
    Summary NextEra Energy, Inc. (NEE), formerly FPL Group, Inc., is an energy company that generates, transmits and distributes electricity together with its subsidiaries. The company generates power through various sources such as nuclear, coal, oil and natural gas-fired facilities, and hydro power pl …
  • China Shipbuilding Industry Corp:企業の戦略・SWOT・財務情報
    China Shipbuilding Industry Corp - Strategy, SWOT and Corporate Finance Report Summary China Shipbuilding Industry Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • China Aviation Oil (Singapore) Corporation Ltd (G92):企業の財務・戦略的SWOT分析
    China Aviation Oil (Singapore) Corporation Ltd (G92) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Uranium One Inc:企業の戦略的SWOT分析
    Uranium One Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Banca Dello Stato Del Cantone Ticino:企業の戦略・SWOT・財務分析
    Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report Summary Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • J.M. Huber Corp:企業の戦略的SWOT分析
    J.M. Huber Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Medison Pharma Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Medison Pharma Ltd (Medison) is a drug company that develops and manufactures medical products. The company's oncology products include vectibix, myocet, aranesp, symphony and coloprint. Its neurology products are avonex, tysabri, fampyra, provigil, stryker, dysport and firdapse. Medison off …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Oberbank AG:企業の戦略・SWOT・財務分析
    Oberbank AG - Strategy, SWOT and Corporate Finance Report Summary Oberbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Brookfield Asset Management Inc.:戦略・SWOT・企業財務分析
    Brookfield Asset Management Inc. - Strategy, SWOT and Corporate Finance Report Summary Brookfield Asset Management Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • PT Bank China Construction Bank Indonesia Tbk:企業の戦略・SWOT・財務分析
    PT Bank China Construction Bank Indonesia Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank China Construction Bank Indonesia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Cap Gemini S.A.:戦略・SWOT・企業財務分析
    Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report Summary Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • TETRA Technologies Inc (TTI):石油・ガス:M&Aディール及び事業提携情報
    Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration and tools services, offshore services, production testing, rig cooling services, technology cen …
  • Capitol Federal Financial Inc:企業の戦略・SWOT・財務分析
    Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆